36 results
8-K
EX-99.1
BTAX
Biostax Corp.
27 Apr 18
Other Events
9:00am
approved, our non-toxic immunotherapy Lodonal™ can have significant impact on the people and communities affected by the HIV epidemic.
Immune Therapeutics
8-K
EX-99.1
BTAX
Biostax Corp.
2 Jun 21
Other Events
9:00am
restructured its toxic convertible promissory Note in default since May of 2018 issued by Iliad Research & Trading, L.P., for $425,000.00 on October 20
8-K
EX-10.1
BTAX
Biostax Corp.
15 May 19
Other Events
12:00am
.
Emerging Markets
To date, we have focused on the emerging nation commercialization of affordable non-toxic immunotherapies Lodonal™ and MENK
S-1
9d2nge4
14 Oct 16
IPO registration
12:00am
DRS/A
k83nc9fr318 fx
14 Oct 16
Draft registration statement (amended)
12:00am